Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Pulmonx (Nasdaq: LUNG) will report its fourth quarter and full year 2025 financial results after market close on Wednesday, March 4, 2026.
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG) will report its fourth quarter and full year 2025 financial results after market close on Wednesday, March 4, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET and a live archived webcast will be available on the company investor website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LUNG
On Feb 20, the day this news came out, LUNG closed 5.99% above the previous close.
Data tracked by StockTitan Argus for the Feb 20 session.
Key Figures
- Earnings release date
- March 4, 2026
- Q4 and full-year 2025 financial results release after market close
- Quarter covered
- Fourth quarter 2025
- Period for upcoming financial results
- Full-year period
- Full year 2025
- Annual results to be reported
- Conference call time PT
- 1:30 p.m. PT
- Scheduled start time for earnings call
- Conference call time ET
- 4:30 p.m. ET
- Scheduled start time for earnings call
Historical Context
-
Large RSU and PSU grants under 2025 Inducement Plan for new executives.
-
Q3 2025 results with revenue growth, high gross margin, and ongoing net loss.
-
CEO change, new COO/CFO, executive departures, and preliminary Q3 revenue update.
-
Announcement of Q3 2025 earnings release date and conference call details.
-
Planned participation in two September 2025 healthcare and growth conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.
Contact
Brian Johnston
Laine Morgan
Gilmartin Group
investors@pulmonx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.